title: Clinical characteristics and prognostic factors of pulmonary MALT lymphoma.
abstract: Mucosa-associated lymphoid tissue-derived (MALT) lymphoma, a low grade B-cell extranodal lymphoma, is the most frequent subset of primary pulmonary lymphoma. Our objective was to evaluate the initial extent of disease and to analyse the characteristics and long-term outcome of these patients. All chest and pathological departments of teaching hospitals in Paris were contacted in order to identify patients with a histological diagnosis of primary pulmonary lymphoma of the MALT subtype. 63 cases were identified. The median age was 60 yrs. 36% of cases had no symptoms at diagnosis. 46% of patients had at least one extrapulmonary location of lymphoma. The estimated 5- and 10-yr overall survival rates were 90% and 72%, respectively. Only two of the nine observed deaths were related to lymphoma. Age and performance status were the only two adverse prognostic factors for survival. Extrapulmonary location of lymphoma was not a prognostic factor for overall survival or for progression-free survival. Treatment with cyclophosphamide or anthracycline was associated with shorter progression-free survival, when compared with chlorambucil. The survival data confirm the indolent nature of pulmonary MALT lymphoma. Better progression-free survival was observed with chlorambucil when compared with cyclophosphamide or anthracycline.
authors.affiliation: Service de Pneumologie et Réanimation, Centre de Compétence Maladies Rares Pulmonaires, Hôpital Tenon, Paris, France.
authors.forename: R
authors.initials: R
authors.lastname: Borie
authors.forename: M
authors.initials: M
authors.lastname: Wislez
authors.forename: G
authors.initials: G
authors.lastname: Thabut
authors.forename: M
authors.initials: M
authors.lastname: Antoine
authors.forename: A
authors.initials: A
authors.lastname: Rabbat
authors.forename: L-J
authors.initials: LJ
authors.lastname: Couderc
authors.forename: I
authors.initials: I
authors.lastname: Monnet
authors.forename: H
authors.initials: H
authors.lastname: Nunes
authors.forename: F-X
authors.initials: FX
authors.lastname: Blanc
authors.forename: H
authors.initials: H
authors.lastname: Mal
authors.forename: A
authors.initials: A
authors.lastname: Bergeron
authors.forename: D
authors.initials: D
authors.lastname: Dusser
authors.forename: D
authors.initials: D
authors.lastname: Israël-Biet
authors.forename: B
authors.initials: B
authors.lastname: Crestani
authors.forename: J
authors.initials: J
authors.lastname: Cadranel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D002699:Chlorambucil / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D002699:Chlorambucil; D003520:Cyclophosphamide